Fast 1.5 T chest MRI for the assessment of interstitial lung disease extent secondary to systemic sclerosis

被引:37
|
作者
Pinal-Fernandez, Iago [1 ,2 ]
Pineda-Sanchez, Victor [3 ,4 ]
Pallisa-Nunez, Esther [3 ,4 ]
Pilar Simeon-Aznar, Carmen [1 ]
Selva-O'Callaghan, Albert [1 ]
Fonollosa-Pla, Vicente [1 ]
Vilardell-Tarres, Miquel [1 ]
机构
[1] Vall dHebron Univ Hosp, Autoimmune System Dis Unit, Dept Internal Med, Barcelona, Spain
[2] NIAMSD, Muscle Dis Unit, Lab Muscle Stem Cells & Gene Express, NIH, 50 South Dr,Room 1141,Bldg 50,MSC 8024, Bethesda, MD 20892 USA
[3] Univ Autonoma Barcelona, Vall dHebron Univ Hosp, Dept Radiol, Barcelona, Spain
[4] NIAMSD, Barcelona, Spain
关键词
Computed x-ray tomography; Interstitial lung diseases; Magnetic resonance imaging; Pulmonary function test; Systemic sclerosis; COMPUTED-TOMOGRAPHY; RADIATION-EXPOSURE; CLASSIFICATION; CT; CRITERIA; FIBROSIS;
D O I
10.1007/s10067-016-3267-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This study aims to evaluate the utility of magnetic resonance imaging (MRI) to assess interstitial lung disease (ILD) extent in patients with systemic sclerosis (SSc). Patients with SSc and varying degrees of ILD with a high-resolution computed tomography (HRCT), pulmonary function tests (PFTs), and a chest MRI containing an ultrafast SE sequence performed less than 1 year apart were included in the study. Wells global disease extent and Goh's staging algorithm were used to measure and categorize ILD both for MRI and HRCT. Correlation and diagnostic performance of MRI compared with HRCT and PFTs were calculated. Eighteen SSc patients were studied. MRI showed a good performance to detect ILD (AUC = 0.96) and was correlated with forced vital capacity (r = -0.60, p = 0.01), diffusing capacity of the lung for carbon monoxide (r = -0.79, p = 0.04), and also with HRCT (r = 0.85, p < 0.001), but MRI extent values were consistently lower than HRCT and, thus, not directly comparable. Goh's algorithm using HRCT and transformed to be used with MRI showed a good agreement (kappa = 0.73, p < 0.001) and MRI-measured ILD extent presented good intra-observer (ICC = 0.86) and inter-observer (ICC = 0.90) reliability. In SSc patients, MRI proved to be a good technique to detect and categorize ILD extent compared with HRCT, suggesting that it may be a valuable x-ray sparing technique for selected cases.
引用
收藏
页码:2339 / 2345
页数:7
相关论文
共 50 条
  • [1] Fast 1.5 T chest MRI for the assessment of interstitial lung disease extent secondary to systemic sclerosis
    Iago Pinal-Fernandez
    Victor Pineda-Sanchez
    Esther Pallisa-Nuñez
    Carmen Pilar Simeon-Aznar
    Albert Selva-O’Callaghan
    Vicente Fonollosa-Pla
    Miquel Vilardell-Tarres
    Clinical Rheumatology, 2016, 35 : 2339 - 2345
  • [2] COMPARISON OF FAST 1.5T CHEST MRI WITH HRCT SCAN IN THE ASSESSMENT OF INTERSTITIAL LUNG DISEASE EXTENSION SECONDARY TO SYSTEMIC SCLEROSIS
    Pinal-Fernandez, I.
    Pineda-Sanchez, V.
    Pallisa Nunez, E.
    Simeon-Aznar, C. P.
    Selva-O'Callaghan, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 706 - 706
  • [3] Chest MRI with CT in the assessment of interstitial lung disease progression in patients with systemic sclerosis
    Hochhegger, Bruno
    Lonzetti, Lilian
    Rubin, Adalberto
    de Mattos, Juliane Nascimento
    Verma, Nupur
    Mohammed, Tan-Lucien H.
    Patel, Pratik P.
    Marchiori, Edson
    RHEUMATOLOGY, 2022, 61 (11) : 4420 - 4426
  • [4] Advanced and traditional chest MRI sequence for the clinical assessment of systemic sclerosis related interstitial lung disease, compared to CT: disease extent analysis and correlations with pulmonary function tests
    Landini, Nicholas
    Orlandi, Martina
    Calistri, Linda
    Nardi, Cosimo
    Ciet, Pierluigi
    Bellando-Randone, Silvia
    Guiducci, Serena
    Benkert, Thomas
    Panebianco, Valeria
    Morana, Giovanni
    Matucci-Cerinic, Marco
    Colagrande, Stefano
    EUROPEAN JOURNAL OF RADIOLOGY, 2024, 170
  • [5] Automatic Quantification of Interstitial Lung Disease From Chest Computed Tomography in Systemic Sclerosis
    Carvalho, Alysson Roncally S.
    Guimaraes, Alan R.
    Sztajnbok, Flavio R.
    Rodrigues, Rosana Souza
    Silva, Bruno Rangel Antunes
    Lopes, Agnaldo Jose
    Zin, Walter Araujo
    Almeida, Isabel
    Franca, Manuela Maria
    FRONTIERS IN MEDICINE, 2020, 7
  • [6] Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease
    Moore, Owen A.
    Goh, Nicole
    Corte, Tamera
    Rouse, Hannah
    Hennessy, Oliver
    Thakkar, Vivek
    Byron, Jillian
    Sahhar, Joanne
    Roddy, Janet
    Gabbay, Eli
    Youssef, Peter
    Nash, Peter
    Zochling, Jane
    Proudman, Susanna M.
    Stevens, Wendy
    Nikpour, Mandana
    RHEUMATOLOGY, 2013, 52 (01) : 155 - 160
  • [7] Lung Ultrasound B-Lines in the Evaluation of the Extent of Interstitial Lung Disease in Systemic Sclerosis
    Bruni, Cosimo
    Mattolini, Lavinia
    Tofani, Lorenzo
    Gargani, Luna
    Landini, Nicholas
    Roma, Nicola
    Lepri, Gemma
    Orlandi, Martina
    Guiducci, Serena
    Bellando-Randone, Silvia
    Romei, Chiara
    Wang, Yukai
    Matucci-Cerinic, Marco
    DIAGNOSTICS, 2022, 12 (07)
  • [8] Pleuroparenchymal fibroelastosis in systemic sclerosis-associated interstitial lung disease
    Sari, Alper
    Onder, Omer
    Armagan, Berkan
    Bolek, Ertugrul Cagri
    Farisogullari, Bayram
    Bilgin, Emre
    Yardimci, Gozde Kubra
    Ariyurek, Macit
    Akdogan, Ali
    TURKISH JOURNAL OF MEDICAL SCIENCES, 2022, 52 (01) : 83 - 88
  • [9] Assessment of interstitial lung disease in systemic sclerosis using the quantitative CT algorithm CALIPER
    Ferrazza, Alessandro Maria
    Gigante, Antonietta
    Gasperini, Maria Ludovica
    Ammendola, Rosa Maria
    Paone, Gregorino
    Carbone, Iacopo
    Rosato, Edoardo
    CLINICAL RHEUMATOLOGY, 2020, 39 (05) : 1537 - 1542
  • [10] Interstitial Lung Disease Associated with Systemic Sclerosis
    Mismetti, Valentine
    Si-Mohamed, Salim
    Cottin, Vincent
    SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 45 (03) : 342 - 364